[go: up one dir, main page]

CO5261535A1 - Combinacion farmaceutica util para el tratamiento de movilidad gastrointestinal alterada, sensibilidad de secrecion, o desordenes abdominales - Google Patents

Combinacion farmaceutica util para el tratamiento de movilidad gastrointestinal alterada, sensibilidad de secrecion, o desordenes abdominales

Info

Publication number
CO5261535A1
CO5261535A1 CO00093154A CO00093154A CO5261535A1 CO 5261535 A1 CO5261535 A1 CO 5261535A1 CO 00093154 A CO00093154 A CO 00093154A CO 00093154 A CO00093154 A CO 00093154A CO 5261535 A1 CO5261535 A1 CO 5261535A1
Authority
CO
Colombia
Prior art keywords
treatment
pharmaceutical combination
abdominal disorders
altered gastrointestinal
gastrointestinal mobility
Prior art date
Application number
CO00093154A
Other languages
English (en)
Inventor
Stephan Anthony Billstein
Peter Dumovic
Franco Niola
Mark Thomas Iwcki
Hans-Jurgen Pfannkuche
Edward Joseph Wilusz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5261535A1 publication Critical patent/CO5261535A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con una combinación de un primer agente que incluye un agonista o antagonista del receptor de 5-HT4 o un antagonista del receptor de 5-HT3, y un coagente, y a composiciones y formulaciones farmacéuticas que contienen la combinación. La combinación farmacéutica se puede emplear para el tratamiento de movilidad gastrointestinal alterada, sensibilidad, secreción, o desórdenes abdominales. La dosificación de preferencia es oral, y la administración de preferencia es una o dos veces al día. El primer agente preferido es tegaserod.
CO00093154A 1999-12-10 2000-12-06 Combinacion farmaceutica util para el tratamiento de movilidad gastrointestinal alterada, sensibilidad de secrecion, o desordenes abdominales CO5261535A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45838899A 1999-12-10 1999-12-10

Publications (1)

Publication Number Publication Date
CO5261535A1 true CO5261535A1 (es) 2003-03-31

Family

ID=23820591

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00093154A CO5261535A1 (es) 1999-12-10 2000-12-06 Combinacion farmaceutica util para el tratamiento de movilidad gastrointestinal alterada, sensibilidad de secrecion, o desordenes abdominales

Country Status (30)

Country Link
EP (3) EP1488788A1 (es)
JP (1) JP2003523324A (es)
KR (1) KR100765579B1 (es)
CN (2) CN1310644C (es)
AR (1) AR026916A1 (es)
AT (1) ATE293971T1 (es)
AU (2) AU778869B2 (es)
BR (1) BR0016275A (es)
CA (1) CA2388959A1 (es)
CO (1) CO5261535A1 (es)
CZ (1) CZ300690B6 (es)
DE (1) DE60019814T2 (es)
DK (1) DK1286668T3 (es)
ES (1) ES2240229T3 (es)
HU (1) HUP0301122A3 (es)
IL (2) IL149496A0 (es)
MX (1) MXPA02005695A (es)
MY (1) MY133423A (es)
NO (1) NO20022680L (es)
NZ (2) NZ566800A (es)
PE (1) PE20011030A1 (es)
PL (1) PL202201B1 (es)
PT (1) PT1286668E (es)
RU (1) RU2264215C2 (es)
SG (1) SG152025A1 (es)
SK (1) SK8062002A3 (es)
TR (1) TR200402293T2 (es)
TW (1) TWI263496B (es)
WO (1) WO2001041748A2 (es)
ZA (1) ZA200204493B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003533482A (ja) * 2000-05-18 2003-11-11 グラクソ グループ リミテッド 機能性消化不良の治療方法
GB0209481D0 (en) * 2002-04-24 2002-06-05 Novartis Ag Organic compounds
EP1567163B1 (en) 2003-01-13 2007-04-11 Dynogen Pharmaceuticals Inc. Method of treating nausea, vomiting, retching or any combination thereof
GB0307440D0 (en) * 2003-03-31 2003-05-07 Novartis Ag Organic compounds
AU2004243444A1 (en) * 2003-05-27 2004-12-09 Altana Pharma Ag Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility
US20050090554A1 (en) * 2003-09-12 2005-04-28 John Devane Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists
US7820690B2 (en) 2004-03-19 2010-10-26 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
CA2573209A1 (en) * 2004-07-14 2006-01-19 Novartis Ag Combination of dpp-iv inhibitors and compounds modulating 5-ht3 and/or 5-ht4 receptors
MX2007009136A (es) * 2005-01-31 2007-09-06 Novartis Ag Uso de agonista de 5-ht4 para tratar vacio gastrico retrasado que puede inducirse por un inhibidor de bomba de protones.
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8354434B2 (en) 2006-01-30 2013-01-15 Purdue Pharma L.P. Cyclourea compounds as calcium channel blockers
US20090163551A1 (en) * 2006-06-15 2009-06-25 Novartis Ag Compositions and Methods for Treating Diseases
US9371297B2 (en) 2007-02-09 2016-06-21 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
WO2009064460A2 (en) 2007-11-13 2009-05-22 Meritage Pharma, Inc. Gastrointestinal delivery systems
US8865692B2 (en) 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
BR112018076281A2 (pt) 2016-06-20 2019-03-26 Kymab Limited imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo
CA3032897A1 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
TW202313682A (zh) 2021-05-18 2023-04-01 英商凱麥博有限公司 抗icos抗體之用途
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
EP4525991A1 (en) 2022-05-18 2025-03-26 Kymab Limited Uses of anti-icos antibodies
FR3144752A1 (fr) 2023-01-10 2024-07-12 Song Huang Utilisation de polysulfate de pentosane pour le traitement de la toux seche

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
DE69226961T2 (de) * 1991-12-21 1999-04-29 Smithkline Beecham P.L.C., Brentford, Middlesex Verwendung von 5-ht4 - antagonisten zur herstellung eines arzneimittels zur behandlung von harninkontinenz
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
PT1286668E (pt) 2005-08-31
IL149496A (en) 2009-12-24
EP1286668B1 (en) 2005-04-27
MXPA02005695A (es) 2002-09-18
CN1310644C (zh) 2007-04-18
NO20022680D0 (no) 2002-06-06
NO20022680L (no) 2002-08-12
PL355663A1 (en) 2004-05-04
CA2388959A1 (en) 2001-06-14
EP1913944A1 (en) 2008-04-23
BR0016275A (pt) 2002-08-27
KR20030016208A (ko) 2003-02-26
PL202201B1 (pl) 2009-06-30
MY133423A (en) 2007-11-30
EP1488788A1 (en) 2004-12-22
HUP0301122A3 (en) 2005-03-29
TWI263496B (en) 2006-10-11
JP2003523324A (ja) 2003-08-05
WO2001041748A3 (en) 2002-12-19
RU2264215C2 (ru) 2005-11-20
CZ20021967A3 (cs) 2002-08-14
PE20011030A1 (es) 2001-10-31
AR026916A1 (es) 2003-03-05
RU2002118316A (ru) 2004-02-20
AU2005200797B2 (en) 2008-01-24
TR200402293T2 (tr) 2004-10-21
ES2240229T3 (es) 2005-10-16
NZ531489A (en) 2005-09-30
AU778869B2 (en) 2004-12-23
AU2005200797A1 (en) 2005-03-17
AU2672801A (en) 2001-06-18
WO2001041748A2 (en) 2001-06-14
IL149496A0 (en) 2002-11-10
CZ300690B6 (cs) 2009-07-15
CN1875966A (zh) 2006-12-13
DE60019814T2 (de) 2006-03-02
KR100765579B1 (ko) 2007-10-09
DK1286668T3 (da) 2005-08-15
DE60019814D1 (de) 2005-06-02
SK8062002A3 (en) 2003-04-01
HUP0301122A2 (hu) 2003-08-28
ATE293971T1 (de) 2005-05-15
EP1286668A2 (en) 2003-03-05
ZA200204493B (en) 2003-09-29
CN1409634A (zh) 2003-04-09
SG152025A1 (en) 2009-05-29
NZ566800A (en) 2009-11-27

Similar Documents

Publication Publication Date Title
CO5261535A1 (es) Combinacion farmaceutica util para el tratamiento de movilidad gastrointestinal alterada, sensibilidad de secrecion, o desordenes abdominales
EA200000718A1 (ru) Композиции целекоксиба
NO20052019L (no) Blanding for a inhibere sekresjon av magesyre
MXPA05008838A (es) Formulaciones de absorcion acelerada del agonista selectivo de la 5-ht.
PT1041987E (pt) Forma farmaceutica de dosagem oral, compreendendo uma combinacao de um agonista de opioide e naltrexona
HUP0001089A2 (hu) Gyógyászati készítmények férfiak erekciós zavarainak kezelésére
BR0010138A (pt) Moduladores de receptores de glucocorticóides
MA29744B1 (fr) Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree
EA200101026A1 (ru) Предварительно желатинированный крахмал в композиции с контролируемым высвобождением
EA202191079A1 (ru) Способы лечения синдрома ретта с применением фенфлурамина
BR0309969A (pt) Uso de compostos que são eficazes como moduladores de receptores seletivos de opiáceos
WO2004017896A3 (en) Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
EA200500985A1 (ru) Твердая лекарственная форма для перорального применения
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
DK1303278T3 (da) Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme
BRPI0414558A (pt) composição farmacêutica compreendendo um antagonista do receptor p2x7 e uma droga antiinflamatória não esteróide
WO2007071394A3 (en) Combination of a 5-ht4 agonist with a cholinesterase inhibitor
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
MXPA04005420A (es) Composicion farmaceutica que comprende un agonista de receptor de 5ht1.
BRPI0412430A (pt) polipeptìdeo agonista do receptor de zot e zonulina
HUP0401042A2 (hu) Primer álmatlanság kezelésére alkalmas gyógyszerkészítmények
HUP0202931A2 (hu) Egy gyógyszerészetileg hatásos összetétel és a beadására szolgáló készülék
AR038858A1 (es) Combinacion
HRP20090225T1 (en) Pharmaceutical compositions based on nk2 antagonists for pediatric use
PE20040670A1 (es) Nuevas composiciones farmaceuticas que contienen ambroxol y yoduro de isopropamida

Legal Events

Date Code Title Description
FC Application refused